First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA+ breast cancer patients
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib ...
Jun 4, 2018
0
5